PepGen
在场
高管
查看带有其 21 名主要高管的组织结构图
PepGen 搜索最多的简介
- James McArthur, Chief Executive Officer and Executive Board Member
- Howard Mayer, Director
- Heidi Henson, Director
高管在PepGen变化
- Chris Ashton, Non-Executive Director, 将于 20249月30 退休 (新闻发布的2024九月20号).
- Paul Streck已作为Executive Vice President, Head of Research & Development加入公司 (新闻发布的2024八月21号).
- Afsaneh Mohebbi已作为Senior Vice President, Portfolio and Program Management加入公司 (新闻发布的2024七月2号).
创建提醒
跟踪 PepGen 的高管变动
健康
PepGen 拥有 1,966 家竞争者，其中包括 Siemens Healthineers (德国)、IQVIA (美国(美洲)) 和 Nestlé Health Science (瑞士)。
Popular M&A news in 健康
- Radon Medical Imaging 已收购 Alpha Imaging (公布2024十一月20号).
- TowerBrook Capital Partners 已收购 R1 RCM (公布2024十一月19号).
- Kewaunee Scientific 已收购 Nu Aire (公布2024十一月6号).
健康 行业的其他推荐联系人
消息
PepGen 的最新新闻稿
- PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors | PepGen
- News Releases | PepGen
- PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments | PepGen
- Scientific Publications | PepGen
- PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) | PepGen
- PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society | PepGen
- PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 | PepGen
- PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences | PepGen
- PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference | PepGen
- PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments | PepGen
- View more press releases Close
关于 PepGen 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 James McArthur 
